ERBB2 and breast carcinoma: In the work reported by Welsher et al., polyethyleneglycol (PEG)-modified SWNTs are conjugated to Rituxan antibodies to selectively recognize CD20 cell surface receptor on B cells with little nonspecific binding to negative T cells and Herceptin antibodies to recognize HER2/neu-positive breast cancer cells.